Live Terminal
Telegram

Five pharma CDMO stocks with robust revenue growth in Q2FY27

Share on WhatsApp Telegram
⚡ Instant Key Takeaways (TL;DR)
🎯
Core Development: Five pharma CDMO stocks with robust revenue growth in Q2FY27
📊
Market & Financial Impact: Discover five CDMO stocks demonstrating strong growth momentum in Q2FY27, backed by rising revenues and expanding opportunities.
💡
Actionable Insight: 🟢 Bullish Trigger: Positive business expansion or earnings beat may attract institutional and retail buying.

Global pharmaceutical companies are increasingly outsourcing research and manufacturing to diversify supply chains and lower costs.

Indian contract development and manufacturing organisations (CDMOs) have emerged as key beneficiaries, moving up the value chain into complex custom synthesis, peptides, and specialty intermediates.

While broader pharmaceutical earnings remained mixed in the September 2026 quarter, select CDMO stocks stood out with strong commercial scale-up and delivered robust revenue growth in Q2FY27. Take a look.

Blue Jet Healthcare is a speciality pharmaceutical CDMO engaged in developing and manufacturing advanced intermediates, APIs and high-intensity sweeteners.

Its business spans three segments: Contrast Media Intermediates for CT, X-ray and MRI imaging agents; Pharma Intermediates & APIs catering to chronic therapies such as CVS, oncology and CNS; and High-Intensity Sweeteners, including saccharin, supplied to global food, beverage and oral care companies.

📰
Official Publisher Attribution: This report is aggregated from LiveMint. ZeroLive provides live aggregation, automated sentiment synthesis, and exchange disclosure monitoring for retail market participants.
Read Original Full Coverage on LiveMint ↗
⚡
Get Breaking Stock Alerts & Q-Results on Telegram
Real-time 1200x675 image cards and financial filings delivered instantly.
Join @Zerolive_news ↗
Link copied to clipboard! ✅